An interventional study of Reveal LINQTM in Stroke, Acute, Stroke and Stroke, Ischemic, sponsored by National and Kapodistrian University of Athens. Recruiting at 1 site in Greece. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-11-09.
Sponsored by National and Kapodistrian University of Athens · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Ischemic Stroke with a site in Greece — 8 open to participants now, 11 under way, 4 of them phase 3. Ischemic Stroke · Greece.
Among the 25 studies in Ischemic Stroke with a site in Greece, this one is the 15th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2023, is one of 2 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 16th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →8 of the 25 studies in Ischemic Stroke with a site in Greece are open now. Recruiting first, the newest first:
Takeda · Sites in Greece, United States, Belgium and 7 more countries
Ages 18+
Boehringer Ingelheim · Sites in Greece, Argentina, Australia and 13 more countries
Ages 18+
Corxel Pharmaceuticals · Sites in Greece, United States, Belgium and 18 more countries
Ages 18–90
Insel Gruppe AG, University Hospital Bern · Sites in Greece, Austria, Belgium and 9 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Greece, Austria, Belgium and 12 more countries
Ages 18+
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 40 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 3
First in 2003; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 866 across the 16 interventional studies, 2,000 across the 9 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 25 have an industry lead sponsor. The 10 most frequent:
National and Kapodistrian University of Athens is the lead sponsor of 178 studies on the registry; 56 are open to participants now.
National and Kapodistrian University of Athens has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Ischemic Stroke with a site in Greece that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07361302Phase 3Boehringer IngelheimA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | 2027-10-02 |
| NCT05494034National and Kapodistrian University of AthensYield of Implantable Cardiac Monitoring Device in Patients With Acute Ischemic Stroke. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Ischemic Stroke with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this prospective cohort study, the investigators aim to investigate the incidence of ICM-detected AF in unselected ischemic stroke patients and its association with anticoagulation initiation and stroke recurrence.
The study will be conducted among 4 tertiary centers of the cardioneurology network in the Athens Metropolitan area ("Attikon" University Hospital, Hippokrateion Hospital, "Georgios Gennimatas" General Hospital of Athens, NIMITS General Hospital of Athens). The Second Department of Neurology of the National and Kapodistrian University of Athens in "Attikon" University Hospital would also act as the coordinating center, comprising of a research group with significant clinical experience and numerous publications on PCM and stroke.
Consecutive acute ischemic stroke or TIA patients aged 40 years or older will be enrolled. Diagnosis of acute ischemic stroke will be based on clinical and neuroimaging evaluation [brain computed tomography (CT) scan or magnetic resonance imaging (MRI) scan]. Classification of stroke will be defined using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. Patients with incomplete evaluation will be excluded, as previously described. Patients with known or newly detected AF at hospitalization will also be excluded. Stroke patients of all other etiologies presenting a HAVOC score ≥4 will be included in the study. Informed consent for participation in the study will be obtained from the patients or guardians of patients.
Sample size
Similar to previous studies, approximately 200 eligible patients will be recruited during a 4-year period (50 patients/year). Based on a retrospective analysis of the local stroke registry and considering the eligibility criteria for this study, it is estimated that at least 1,000 stroke patients should be screened in order to enroll 200 participants.
Baseline Evaluation
All demographics and vascular risk factors will be prospectively recorded for all patients using standard definitions. Complete hematological and biochemical screening, as well as immunological and thrombophilia testing where indicated, will be performed. A comprehensive stroke etiopathogenic evaluation will be performed, including neuroimaging with brain computed tomography (CT) and / or magnetic resonance imaging (MRI), vascular imaging (cervical duplex ultrasound, transcranial Doppler, CT angiography and / or magnetic resonance [MR] angiography), ECG, transthoracic and/or transesophageal echocardiography and 24-to-48-hour Holter-ECG monitoring.
In particular, among the risk factors assessed, the age at inclusion, the number of atrial premature beats during the Holter-ECG monitoring, the location of index ischemic stroke (cortical versus deep), the brain natriuretic peptide (BNP) values, the presence of left atrial enlargement as diagnosed according to the guidelines of the American Society of Echocardiography, the HAVOC score (hypertension, age, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, coronary artery disease), the CHA₂DS₂-VASc score and the HAS-BLED score will be also recorded.
Stroke severity on admission will be assessed with the use of the National Institute of Health Stroke Scale (NIHSS) score by certified neurologists. Stroke classification according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) will be performed by certified neurologists, comprising of five stroke subtypes: (a) large-artery atherosclerosis; (b) cardioembolism; (c) small-vessel occlusion; (d) stroke of other determined etiology; and (e) stroke of undetermined etiology.[23] Interventions All included patients will receive secondary stroke prevention treatment and long-term management depending on the stroke subtype and according to current guidelines.
All included patients will have long-term heart rate monitors (Reveal LINQ; Medtronic) implanted subcutaneously under local anesthesia in the left chest region. During monitoring time, all patients with ICM will be evaluated clinically and electrocardiographically for up to 3 years following hospital discharge. Follow-up visits will be performed at the stroke outpatient clinic of our institution by outpatient visits and / or telephone, as dictated by their clinical status and at the discretion of the treating vascular neurologist, as previously described. All ICM recordings will be reviewed by a specialized cardiologist. All included patients will also be monitored with annual MRI scans for up to 3 years.
In the cases of AF detection, anticoagulant treatment may be initiated at the discretion of the treating physician, considering that the CHA₂DS₂-VASc score of the included patients will be at least 2 points, due to the history of stroke.
Statistical Analysis
Continuous variables will be presented as mean ± SD (normal distribution) and as median with interquartile range (IQR, skewed distribution). Categorical variables will be presented as number of patients and the corresponding percentages. Statistical comparisons between two groups (AF detected and no-AF detected) will be performed using χ2 test, or in case of small expected frequencies, Fisher's exact test. Continuous variables will be compared by the use of the unpaired t test or Mann-Whitney U test, as indicated. Cumulative probabilities of AF by risk factors will be displayed according to the Kaplan-Meier method. Event rates will be compared using the log-rank statistic. Univariable and multivariable Cox proportional hazards regression models will be used to determine predictors of AF. Baseline variables having differences with a significance level \<0.10 will be considered as candidates for multivariable time-to-event AF models. Statistical significance will be achieved if the p value is ⩽0.05 in multivariable logistic regression analyses. The Statistical Package for Social Science (SPSS Inc, Armonk, NY, USA; version 23.0 for Windows) will be used for statistical analyses.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
This study's planned enrollment of 200 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →National and Kapodistrian University of Athens is the lead sponsor of 178 studies on the registry; 56 are open to participants now.
Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All included patients will have long-term heart rate monitors (Reveal LINQ; Medtronic)
Device: Reveal LINQTM
implantable cardiac monitoring device ("Reveal LINQTM")
Paroxysmal Atrial Fibrillation > 120 seconds
the incidence of paroxysmal AF lasting 120 seconds or more in included patients evaluated with ICM.
Time frame: 3 years
Paroxysmal Atrial Fibrillation > 6 minutes
B) the incidence of paroxysmal AF lasting 6 minutes or more in included patients evaluated with ICM.
Time frame: 3 years
anticoagulant initiation
C) the incidence of anticoagulant initiation among included patients.
Time frame: 3 years
recurrent ischemic strokes
D) the incidence of recurrent ischemic strokes in included patients evaluated with ICM at follow-up according to paroxysmal AF duration.
Time frame: 3 years
subclinical infracts on follow-up MRI
E) the incidence of subclinical infracts on follow-up MRI scans according to paroxysmal AF duration.
Time frame: 3 years
major hemorrhagic events
F) the incidence of major hemorrhagic events in included patients evaluated with ICM at follow-up according to paroxysmal AF duration.
Time frame: 3 years
stroke subtypes
G) the possible correlation between stroke subtypes and AF detection.
Time frame: 3 years
biomarkers
H) the possible correlation of several baseline risk factors (including age, stroke location, BNP values, number of atrial premature beats, left atrial enlargement, HAVOC, CHA₂DS₂-VASc and HAS-BLED scores) with AF detection.
Time frame: 3 years
comparison versus historical cohort
I) the comparison of the rates of recurrent stroke among the patients included in the present cohort and undergoing ICM versus historical controls that were evaluated by the standard 24-hour Holter-ECG monitoring.
Time frame: 3 years
Started May 2023 (actual). Primary completion is estimated for Jan 2027, 43 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 43 months is above that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National and Kapodistrian University of Athens →